All In Biotech

Drug Trial Radar · NCT00996580

A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy

A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-103) for the Prevention of Pregnancy in Women

Last checked: Nov 19, 2026Latest source record: Jun 24, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,597

Actual

Start

Oct 2009

Primary completion

Sep 2011

Study completion Sep 2011

Sponsor

Lead sponsor
Teva Women's HealthTeva (TEVA)
Sponsor type
Industry
First posted
Oct 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, single-treatment study. All subjects will receive 12 months of oral contraceptive therapy with DR-103. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.

Conditions

  • Pregnancy Prevention

Interventions

  • DR-103Drug

    One tablet daily. Four 91-day cycles of the DR-103 regimen: 42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant WeightTime frame: Day 1 up to year 1
  2. Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant WeightTime frame: Day 1 up to year 1
  3. Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant WeightTime frame: Day 1 up to year 1
  4. All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant WeightTime frame: Day 1 up to year 1
  5. Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant WeightTime frame: Day 1 up to year 1
  6. Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant WeightTime frame: Day 1 up to year 1
  7. Summary of Participants With Treatment-emergent Adverse EventsTime frame: Day 1 up to 13 months

Locations

94 sites in 1 country. Site status is shown where the registry gives one.

  • Teva Women's Health Research Investigational Site

    Montgomery, Alabama

  • Teva Women's Health Research Investigational Site

    Phoenix, Arizona

  • Teva Women's Health Research Investigational Site

    Phoenix, Arizona

  • Teva Women's Health Research Investigational Site

    Tucson, Arizona

  • Teva Women's Health Research Investigational Site

    Little Rock, Arkansas

  • Teva Women's Health Research Investigational Site

    Anaheim, California

  • Teva Women's Health Research Investigational Site

    Irvine, California

  • Teva Women's Health Research Investigational Site

    Los Angeles, California

  • Teva Women's Health Research Investigational Site

    National City, California

  • Teva Women's Health Research Investigational Site

    San Diego, California

  • Teva Women's Health Research Investigational Site

    San Diego, California

  • Teva Women's Health Research Investigational Site

    San Diego, California

  • Teva Women's Health Research Investigational Site

    San Francisco, California

  • Teva Women's Health Research Investigational Site

    Torrance, California

  • Teva Women's Health Research Investigational Site

    Colorado Springs, Colorado

  • Teva Women's Health Research Investigational Site

    Pueblo, Colorado

  • Teva Women's Health Research Investigational Site

    Washington D.C., District of Columbia

  • Teva Women's Health Research Investigational Site

    Clearwater, Florida

  • Teva Women's Health Research Investigational Site

    Jacksonville, Florida

  • Teva Women's Health Research Investigational Site

    Leesburg, Florida

  • Teva Women's Health Research Investigational Site

    Miami, Florida

  • Teva Women's Health Research Investigational Site

    Miami, Florida

  • Teva Women's Health Research Investigational Site

    New Port Richey, Florida

  • Teva Women's Health Research Investigational Site

    Palm Beach, Florida

  • Teva Women's Health Research Investigational Site

    St. Petersburg, Florida

  • Teva Women's Health Research Investigational Site

    Tampa, Florida

  • Teva Women's Health Research Investigational Site

    West Palm Beach, Florida

  • Teva Women's Health Research Investigational Site

    Atlanta, Georgia

  • Teva Women's Health Research Investigational Site

    Decatur, Georgia

  • Teva Women's Health Research Investigational Site

    Roswell, Georgia

  • Teva Women's Health Research Investigational Site

    Sandy Springs, Georgia

  • Teva Women's Health Research Investigational Site

    Savannah, Georgia

  • Teva Women's Health Research Investigational Site

    Meridian, Idaho

  • Teva Women's Health Research Investigational Site

    Champaign, Illinois

  • Teva Women's Health Research Investigational Site

    Wichita, Kansas

  • Teva Women's Health Research Investigational Site

    Lexington, Kentucky

  • Teva Women's Health Research Investigational Site

    Louisville, Kentucky

  • Teva Women's Health Research Investigational Site

    Mount Sterling, Kentucky

  • Teva Women's Health Research Investigational Site

    Baton Rouge, Louisiana

  • Teva Women's Health Research Investigational Site

    Metairie, Louisiana

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.